EPS for Omeros Corporation (OMER) Expected At $-0.16

February 15, 2018 - By Dolores Ford

 EPS for Omeros Corporation (OMER) Expected At $ 0.16
Investors sentiment increased to 2.86 in Q3 2017. Its up 1.59, from 1.27 in 2017Q2. It is positive, as 10 investors sold Omeros Corporation shares while 11 reduced holdings. 22 funds opened positions while 38 raised stakes. 22.04 million shares or 15.32% more from 19.11 million shares in 2017Q2 were reported.
Citadel Advsr Limited owns 65,802 shares for 0% of their portfolio. Next Financial Group Incorporated invested 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Stoneridge Partners Llc accumulated 0.08% or 22,641 shares. Swiss Savings Bank has 75,100 shares for 0% of their portfolio. Alliancebernstein L P holds 61,500 shares. 2,550 were reported by Tru Department Mb Fin Retail Bank N A. Amp Cap Investors stated it has 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Bnp Paribas Arbitrage Sa stated it has 0% in Omeros Corporation (NASDAQ:OMER). Ameritas Prtnrs Inc reported 3,655 shares. D E Shaw & holds 383,281 shares. Bancorporation Of America De holds 0% or 88,859 shares in its portfolio. Blair William & Il holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 9,500 shares. Ubs Asset Americas has invested 0% in Omeros Corporation (NASDAQ:OMER). Cambridge Inv Research Advsrs holds 0% or 11,845 shares. Victory Capital Mgmt holds 0% or 1,570 shares.

Since January 3, 2018, it had 0 insider buys, and 2 sales for $1.36 million activity. On Wednesday, January 3 Kelbon Marcia S. sold $1.34M worth of Omeros Corporation (NASDAQ:OMER) or 62,528 shares.

Analysts expect Omeros Corporation (NASDAQ:OMER) to report $-0.16 EPS on March, 15.They anticipate $0.04 EPS change or 20.00 % from last quarter’s $-0.2 EPS. After having $-0.07 EPS previously, Omeros Corporation’s analysts see 128.57 % EPS growth. The stock decreased 2.22% or $0.25 during the last trading session, reaching $11. About 1.89 million shares traded or 150.05% up from the average. Omeros Corporation (NASDAQ:OMER) has risen 42.59% since February 15, 2017 and is uptrending. It has outperformed by 25.89% the S&P500.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 9 analysts covering Omeros (NASDAQ:OMER), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Omeros had 26 analyst reports since August 10, 2015 according to SRatingsIntel. As per Thursday, January 4, the company rating was maintained by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Tuesday, January 23. The stock has “Outperform” rating by Wedbush on Wednesday, November 16. The stock of Omeros Corporation (NASDAQ:OMER) earned “Buy” rating by Cantor Fitzgerald on Friday, June 3. The company was maintained on Wednesday, August 2 by Maxim Group. As per Tuesday, August 18, the company rating was maintained by Cowen & Co. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 29. Needham maintained the shares of OMER in report on Wednesday, November 11 with “Buy” rating. Cantor Fitzgerald maintained it with “Hold” rating and $1500 target in Tuesday, June 13 report. H.C. Wainwright maintained it with “Buy” rating and $30.0 target in Thursday, December 14 report.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $528.04 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

More news for Omeros Corporation (NASDAQ:OMER) were recently published by: Seekingalpha.com, which released: “Omeros Corporation: What The Positive EMA’s Opinion Regarding OMS-721 Orphan …” on January 23, 2018. Fool.com‘s article titled: “Here’s Why Omeros Corporation Is Getting Beaten Down on Wednesday” and published on February 14, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.